{"id":2295,"date":"2014-08-01T12:05:00","date_gmt":"2014-08-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/neues-zu-dauer-und-intensitaet-der-dualen-plaettchenhemmung-nach-implantation-koronarer-stents"},"modified":"2014-08-01T12:05:00","modified_gmt":"2014-08-01T10:05:00","slug":"neues-zu-dauer-und-intensitaet-der-dualen-plaettchenhemmung-nach-implantation-koronarer-stents","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/neues-zu-dauer-und-intensitaet-der-dualen-plaettchenhemmung-nach-implantation-koronarer-stents","title":{"rendered":"Neues zu Dauer und Intensit\u00e4t der dualen Pl\u00e4ttchenhemmung nach Implantation koronarer Stents"},"content":{"rendered":"<p>\u00dcber die Diskussion zu Dauer und Intensit\u00e4t der dualen Pl\u00e4ttchenhemmung (DAT) nach Implantation koronarer Stents haben wir in der Vergangenheit mehrfach berichtet (vgl. 1). Nach den aktuellen Leitlinien der kardiologischen Fachgesellschaften ist nach Implantation eines unbeschichteten, sog. &#8222;Bare-Metal Stents&#8220; (BMS), eine mindestens einmonatige DAT erforderlich und nach Implantation eines beschichteten, sog. &#8222;Drug-Eluting Stents&#8220; (DES), eine [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00dcber die Diskussion zu Dauer und Intensit\u00e4t der dualen Pl\u00e4ttchenhemmung (DAT) nach Implantation koronarer Stents haben wir in der Vergangenheit mehrfach berichtet (vgl. 1). Nach den aktuellen Leitlinien der kardiologischen Fachgesellschaften ist nach Implantation eines unbeschichteten, sog. &#8222;Bare-Metal Stents&#8220; (BMS), eine mindestens einmonatige DAT erforderlich und nach Implantation eines beschichteten, sog. &#8222;Drug-Eluting Stents&#8220; (DES), eine [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,684,495,4572,1272,2686,77,76,73,71,1172,85,86,498,65,83,84,87,1033,79,882,727],"class_list":["post-2295","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-arctic-studie","tag-arteriosklerose","tag-aspirin-resistenz","tag-ass","tag-azetylsalizylsaeure","tag-clopidogrel","tag-herzinfarkt","tag-koronar-stent","tag-koronarangiografie","tag-koronarangiographie","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-prasugrel","tag-ptca","tag-stent","tag-thrombozytenaggregationshemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2295"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2295\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}